Adial Pharmaceuticals (ADIL) reported a net loss of $52.0 million, or $11.25 per basic and diluted share, for the second quarter ended June 30, 2026. The company reported $28.7 million in cash and cash equivalents at quarter-end.
The company completed its acquisition of Azora Therapeutics, adding AT177, an oral colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis. Adial said it closed an initial $32 million tranche of an up-to-$64 million private placement.
- Research and development expense was $440,000, down from $732,000 a year earlier.
- General and administrative expense was $5.4 million, compared with $1.2 million in the prior-year quarter.
- Acquired in-process research and development expense totaled $46.2 million.
- Adial plans to file an IND for AT177 in the first half of 2027 and begin a Phase 1a trial in the second half of 2027.
$ADIL Insider Trading Activity
$ADIL insiders have traded $ADIL stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ADIL stock by insiders over the last 6 months:
- CAPITAL LP COASTLANDS has made 5 purchases buying 39,986 shares for an estimated $106,328 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ADIL Hedge Fund Activity
We have seen 7 institutional investors add shares of $ADIL stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STONEPINE CAPITAL MANAGEMENT, LLC added 727,563 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,862,561
- ARMISTICE CAPITAL, LLC removed 102,178 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $182,898
- JANE STREET GROUP, LLC added 32,119 shares (+inf%) to their portfolio in Q2 2026, for an estimated $82,224
- CITADEL ADVISORS LLC added 29,547 shares (+inf%) to their portfolio in Q2 2026, for an estimated $75,640
- STONEX GROUP INC. added 19,699 shares (+inf%) to their portfolio in Q2 2026, for an estimated $50,429
- UBS GROUP AG added 18,605 shares (+3432.7%) to their portfolio in Q2 2026, for an estimated $47,628
- GEODE CAPITAL MANAGEMENT, LLC removed 11,856 shares (-48.9%) from their portfolio in Q2 2026, for an estimated $30,351
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
